CCL

Összesen 15 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM101421
035-os BibID:(cikkazonosító)4284 (scopus)85128130388 (wos)000785465100001
Első szerző:Buglyó Gergely (genetikus)
Cím:Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome / Gergely Buglyó, Jakub Styk, Ondrej Pös, Ádám Csók, Vanda Repiska, Beáta Soltész, Tomas Szemes, Bálint Nagy
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Lynch syndrome (LS) is an autosomal dominant inherited cancer predisposition disorder, which may manifest as colorectal cancer (CRC), endometrial cancer (EC) or other malignancies of the gastrointestinal and genitourinary tract as well as the skin and brain. Its genetic cause is a defect in one of the four key DNA mismatch repair (MMR) loci. Testing of patients at risk is currently based on the absence of MMR protein staining and detection of mutations in cancer tissue and the germline, microsatellite instability (MSI) and the hypermethylated state of the MLH1 promoter. If LS is shown to have caused CRC, lifetime follow-up with regular screening (most importantly, colonoscopy) is required. In recent years, DNA and RNA markers extracted from liquid biopsies have found some use in the clinical diagnosis of LS. They have the potential to greatly enhance the efficiency of the follow-up process by making it minimally invasive, reproducible, and time effective. Here, we review markers reported in the literature and their current clinical applications, and we comment on possible future directions.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Lynch syndrome
colorectal cancer
screening
liquid biopsy
circulating nucleic acids
biomarker
Megjelenés:International Journal Of Molecular Sciences. - 23 : 8 (2022), p. 4284. -
További szerzők:Styk, Jakub Pös, Ondrej (1990-) (biológus) Csók Ádám (1994-) (biológus) Repiska Vanda Soltész Beáta (1987-) (molekuláris biológus) Szemes, Tomas (1980-) (biológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM111719
035-os BibID:(cikkazonosító)8793 (WoS)000996948500001 (Scopus)85160377221
Első szerző:Csók Ádám (biológus)
Cím:Alterations of miRNA Expression in Diffuse Hyperplastic Perilobar Nephroblastomatosis : Mapping the Way to Understanding Wilms' Tumor Development and Differential Diagnosis / Csók Ádám, Micsik Tamás, Magyar Zsófia, Tornóczky Tamás, Kuthi Levente, Nishi Yumika, Szirák Krisztina, Csóka Monika, Ottóffy Gábor, Soltész Beáta, Balogh István, Buglyó Gergely
Dátum:2023
ISSN:1422-0067
Megjegyzések:Wilms' tumor (WT) is the most common renal malignancy in children. In diffuse hyperplastic perilobar nephroblastomatosis (DHPLN), nephrogenic rests result in a bulky enlargement of the kidney, a condition considered as a premalignant state before WT. Despite relevant clinical differences between WT and DHPLN, they are often challenging to distinguish based on histology. Molecular markers would improve differential diagnosis, but none are available at present. In our study, we investigated the potential of microRNAs (miRNAs) as such biomarkers, also aiming to shed light on the chronological order of expression changes. Formalin-fixed, paraffin-embedded (FFPE) samples from four DHPLN cases and adjacent healthy tissues were tested using a PCR array containing primers for 84 miRNAs implicated in genitourinary cancer. Expression in DHPLN was compared to WT data available in dbDEMC. Let-7, miR-135, miR-146a-5p, miR-182-5p, miR-183-5p, miR-20b-3p, miR-29b-3p, miR-195-5p and miR-17-5p showed potential to be used as biomarkers to distinguish WT and DHPLN in cases when traditional differential diagnosis is inconclusive. Our study also revealed miRNAs which may play a role in the initial steps of the pathogenesis (at a precancerous stage) and ones which become deregulated later in WT. More experiments are needed to confirm our observations and find new candidate markers.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Wilms' tumor
nephrogenic rest
diffuse hyperplastic perilobar nephroblastomatosis
miRNA
formalin-fixed, paraffin-embedded sample
Megjelenés:International Journal Of Molecular Sciences. - 24 : 10 (2023), p. 1-16. -
További szerzők:Micsik Tamás Magyar Zsófia Tornóczky Tamás Kuthi Levente Nishi, Yumika Szirák Krisztina (1973-) (molekuláris genetikus) Csóka Mónika Ottóffy Gábor Soltész Beáta (1987-) (molekuláris biológus) Balogh István (1972-) (molekuláris biológus, genetikus) Buglyó Gergely (1980-) (genetikus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM080605
035-os BibID:(cikkazonosító)E4119 (PMID)31450846 (scopus)85071765729 (wos)000486888400051
Első szerző:Dvorská, Dana
Cím:Aberrant Methylation Status of Tumour Suppressor Genes in Ovarian Cancer Tissue and Paired Plasma Samples / Dana Dvorská, Dušan Braný, Bálint Nagy, Marián Grendár , Robert Poka, Beáta Soltész, Marianna Jagelková, Katarína Zelinová, Zora Lasabová, Pavol Zubor, Zuzana Danková
Dátum:2019
ISSN:1661-6596 1422-0067
Megjegyzések:Ovarian cancer is a highly heterogeneous disease and its formation is affected by many epidemiological factors. It has typical lack of early signs and symptoms, and almost 70% of ovarian cancers are diagnosed in advanced stages. Robust, early and non-invasive ovarian cancer diagnosis will certainly be beneficial. Herein we analysed the regulatory sequence methylation profiles of the RASSF1, PTEN, CDH1 and PAX1 tumour suppressor genes by pyrosequencing in healthy, benign and malignant ovarian tissues, and corresponding plasma samples. We recorded statistically significant higher methylation levels (p < 0.05) in the CDH1 and PAX1 genes in malignant tissues than in controls (39.06 ? 18.78 versus 24.22 ? 6.93; 13.55 ? 10.65 versus 5.73 ? 2.19). Higher values in the CDH1 gene were also found in plasma samples (22.25 ? 14.13 versus 46.42 ? 20.91). A similar methylation pattern with positive correlation between plasma and benign lesions was noted in the CDH1 gene (r = 0.886, p = 0.019) and malignant lesions in the PAX1 gene (r = 0.771, p < 0.001). The random forest algorithm combining methylation indices of all four genes and age determined 0.932 AUC (area under the receiver operating characteristic (ROC) curve) prediction power in the model classifying malignant lesions and controls. Our study results indicate the effects of methylation changes in ovarian cancer development and suggest that the CDH1 gene is a potential candidate for non-invasive diagnosis of ovarian cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
liquid biopsy
pirosequencing
ovarian cancer
Megjelenés:International Journal of Molecular Sciences. - 20 : 17 (2019), p. 1-19. -
További szerzők:Braný, Dušan Nagy Bálint (1956-) (molekuláris genetikus) Grendar, Marian Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Soltész Beáta (1987-) (molekuláris biológus) Jagelková, Marianna Zelinová, Katarína Lasabova, Zora Zubor, Pavol Danková, Zuzana
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM094352
035-os BibID:(cikkazonosító)5058 (scopus)85105433955 (wos)000662004700001
Első szerző:Géczi Dóra (biotechnológus)
Cím:Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients / Dóra Géczi, Bálint Nagy, Melinda Szilágyi, András Penyige, Álmos Klekner, Adrienn Jenei, József Virga, Zsuzsanna Birkó
Dátum:2021
ISSN:1661-6596 1422-0067
Megjegyzések:Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs?besides being important regulators of cancer development?may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein?protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
circulating miRNA
blood plasma
network analysis
biomarker
NanoString
Megjelenés:International Journal Of Molecular Sciences. - 22 : 10 (2021), p. 1-20. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész) Jenei Adrienn (1978-) (biológus, kémikus) Virga József (1989-) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
NKP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM088377
035-os BibID:(cikkazonosító)7522 (scopus)85092461194 (wos)000585658800001
Első szerző:Hádáné Birkó Zsuzsanna (molekuláris genetikus)
Cím:Novel molecularn markers in glioblastoma : benefits of liquid biopsy / Birkó Zs., Nagy B., Klekner Á., Virga J.
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistochemistry, FISH, or PCR-based molecular markers, including isocitrate dehydrogenase1/2 (IDH1/2) mutations, epidermal growth factor receptor variant III (EGFRvIII) mutation, vascular endothelial growth factor overexpression (VEGF) overexpression, or (O6-Methylguanine-DNA methyltransferase promoter) MGMT promoter methylation status, are well-described; however, their clinical usefulness and accuracy is limited, and tumor tissue samples are always necessary. Liquid biopsy is a developing field of diagnostics and patient follow up in multiple types of cancer. Fragments of circulating nucleic acids are collected in various forms from different bodily fluids, including serum, urine, or cerebrospinal fluid in order to measure the quality and quantity of these markers. Multiple types of nucleic acids can be analyzed using liquid biopsy. Circulating cell-free DNA, mitochondrial DNA, or the more stable long and small non-coding RNAs, circular RNAs, or microRNAs can be identified and measured by novel PCR and next-generation sequencing-based methods. These markers can be used to detect the previously described alterations in a minimally invasive method. These markers can be used to differentiate patients with poor or better prognosis, or to identify patients who do not respond to therapy. Liquid biopsy can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of cancer, measuring circulating tumor-derived nucleic acids from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in glioblastoma as well.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
biomarker
Megjelenés:International Journal Of Molecular Sciences. - 21 (2020), p. 1-14. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész) Virga József (1989-)
Pályázati támogatás:ÚNKP-20-4-II
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM098761
035-os BibID:(cikkazonosító)10005 (scopus)85114918353 (wos)000699643100001
Első szerző:Hutóczki Gábor (Ph.D. hallgató)
Cím:Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity / Hutóczki Gábor, Virga József, Birkó Zsuzsanna, Klekner Almos
Dátum:2021
ISSN:1661-6596 1422-0067
Megjegyzések:Although treatment outcomes of glioblastoma, the most malignant central nervous system (CNS) tumor, has improved in the past decades, it is still incurable, and survival has only slightly improved. Advances in molecular biology and genetics have completely transformed our understanding of glioblastoma. Multiple classifications and different diagnostic methods were made according to novel molecular markers. Discovering tumor heterogeneity only partially explains the ineffectiveness of current anti-proliferative therapies. Dynamic heterogeneity secures resistance to combined oncotherapy. As tumor growth proceeds, new therapy-resistant sub clones emerge. Liquid biopsy is a new and promising diagnostic tool that can step up with the dynamic genetic change. Getting a 'real-time' picture of a specific tumor, anti-invasion and multi-target treatment can be designed. During invasion to the peri-tumoral brain tissue, glioma cells interact with the extracellular matrix components. The expressional levels of these matrix molecules give a characteristic pattern, the invasion spectrum, which possess vast diagnostical, predictive and prognostic information. It is a huge leap forward combating tumor heterogeneity and searching for novel therapies. Using the invasion spectrum of a tumor sample is a novel tool to distinguish between histological subtypes, specifying the tumor grades or different prognostic groups. Moreover, new therapeutic methods and their combinations are under trial. These are crucial steps towards personalized oncotherapy.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
liquid biopsy
invasion spectrum
oncotherapy
Megjelenés:International Journal Of Molecular Sciences. - 22 : 18 (2021), p. 1-15. -
További szerzők:Virga József (1989-) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
Egyéb
ÚNKP-20-4
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM116380
035-os BibID:(cikkazonosító)15334 (WoS)001099393900001 (Scopus)85175276027
Első szerző:Madar László (klinikai laboratóriumi kutató)
Cím:Double Heterozygosity for Rare Deleterious Variants in the BRCA1 and BRCA2 Genes in a Hungarian Patient with Breast Cancer / Madar László, Majoros Viktória, Szűcs Zsuzsanna, Nagy Orsolya, Babicz Tamás, Butz Henriett, Patócs Attila, Balogh István, Koczok Katalin
Dátum:2023
ISSN:1422-0067
Megjegyzések:Hereditary breast cancer is most commonly attributed to germline BRCA1 and BRCA2 gene variants. The vast majority of BRCA1 and BRCA2 mutation carriers are single heterozygotes, and double heterozygosity (DH) is a very rare finding. Here, we describe the case of a BRCA1/BRCA2 double heterozygous female proband diagnosed with breast cancer. Genetic testing for hereditary breast and ovarian cancer revealed two pathogenic variants in the BRCA1 (c.5095C>T, p.(Arg1699Trp)) and in BRCA2 genes (c.658_659delGT, p.(Val220Ilefs*4)) in heterozygous form. None of the variants were founder Jewish mutations; to our knowledge, these rare deleterious variants have not been previously described in DH patients in the literature. The patient had triple-negative unilateral breast cancer at the age of 36 and 44 years. Based on family studies, the BRCA1 variant was maternally inherited.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
BRCA1
BRCA2
double heterozygosity
breast cancer
Megjelenés:International Journal Of Molecular Sciences. - 24 : 20 (2023), p. 1-7. -
További szerzők:Majoros Viktória Szűcs Zsuzsanna (1993-) (molekuláris biológus) Nagy Orsolya (1990-) (PhD hallgató) Babicz Tamás Butz Henriett Patócs Attila Balogh István (1972-) (molekuláris biológus, genetikus) Koczok Katalin (1979-) (labororvos)
Pályázati támogatás:ÚNKP-22-4-I-DE-159
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM090169
035-os BibID:(cikkazonosító)9725 (scopus)85098209070 (wos)000603503300001
Első szerző:Márton Éva (biológus)
Cím:The Cell-Free Expression of MiR200 Family Members Correlates with Estrogen Sensitivity in Human Epithelial Ovarian Cells / Éva Márton, Alexandra Varga, Lajos Széles, Lóránd Göczi, András Penyige, Bálint Nagy, Melinda Szilágyi
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:Exposure to physiological estrogens or xenoestrogens (e.g., zearalenone or bisphenol A) increases the risk for cancer. However, little information is available on their significance in ovarian cancer. We present a comprehensive study on the effect of estradiol, zearalenone and bisphenol A on the phenotype, mRNA, intracellular and cell-free miRNA expression of human epithelial ovarian cell lines. Estrogens induced a comparable effect on the rate of cell proliferation and migration as well as on the expression of estrogen-responsive genes (GREB1, CA12, DEPTOR, RBBP8) in the estrogen receptor ? (ER?)-expressing PEO1 cell line, which was not observable in the absence of this receptor (in A2780 cells). The basal intracellular and cell-free expression of miR200s and miR203a was higher in PEO1, which was accompanied with low ZEB1 and high E-cadherin expression. These miRNAs showed a rapid but intermittent upregulation in response to estrogens that was diminished by an ER?-specific antagonist. The role of ER? in the regulation of the MIR200B-MIR200A-MIR429 locus was further supported by publicly available ChIP-seq data. MiRNA expression of cell lysates correlated well with cell-free miRNA expression. We conclude that cell-free miR200s might be promising biomarkers to assess estrogen sensitivity of ovarian cells.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ovarian cancer
estrogen
zeralenone
bisphenol
estrogen receptor
cell-free miRNA
miR200
miR203a
EMT
Megjelenés:International Journal of Molecular Sciences. - 21 : 24 (2020), p. 1-19. -
További szerzők:Beke-Varga Alexandra Edit (1994-) (molekuláris biológus) Széles Lajos (1971-) (molekuláris biológus) Göczi Loránd (informatikus) Penyige András (1954-) (molekuláris genetikus) Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM081633
035-os BibID:(cikkazonosító)5645 (scopus)85074867843 (wos)000502786800127
Első szerző:Nagy Bálint (molekuláris genetikus)
Cím:Cell-Free Nucleic Acids / Nagy Bálint
Dátum:2019
ISSN:1661-6596 1422-0067
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztői levél
folyóiratcikk
cell free mucleic acids
liquid biopsy
cancer
prenatal diagnosis
bioinformatics
ovarian cancer
microchimerism
Megjelenés:International Journal Of Molecular Sciences. - 20 : 22 (2019), p. 1-4. -
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

10.

001-es BibID:BIBFORM080828
035-os BibID:(cikkazonosító)4533 (scopus)85072531584 (wos)000489100500212
Első szerző:Penyige András (molekuláris genetikus)
Cím:Circulating miRNA Profiling in Plasma Samples of Ovarian Cancer Patients / András Penyige, Éva Márton, Beáta Soltész, Melinda Szilágyi-Bónizs, Róbert Póka, János Lukács, Lajos Széles, Bálint Nagy
Dátum:2019
ISSN:1661-6596 1422-0067
Megjegyzések:Ovarian cancer is one of the most common cancer types in women characterized by a high mortality rate due to lack of early diagnosis. Circulating miRNAs besides being important regulators of cancer development could be potential biomarkers to aid diagnosis. We performed the circulating miRNA expression analysis in plasma samples obtained from ovarian cancer patients stratified into FIGO I, FIGO III, and FIGO IV stages and from healthy females using the NanoString quantitative assay. Forty-five miRNAs were di erentially expressed, out of these 17 miRNAs showed significantly di erent expression between controls and patients, 28 were expressed only in patients, among them 19 were expressed only in FIGO I patients. Di erentially expressed miRNAs were ranked by the network-based analysis to assess their importance. Target genes of the di erentially expressed miRNAs were identified then functional annotation of the target genes by the GO and KEGG-based enrichment analysis was carried out. A general and an ovary-specific protein?protein interaction network was constructed from target genes. Results of our network and the functional enrichment analysis suggest that besides HSP90AA1, MYC, SP1, BRCA1, RB1, CFTR, STAT3, E2F1, ERBB2, EZH2, and MET genes, additional genes which are enriched in cell cycle regulation, FOXO, TP53, PI-3AKT, AMPK, TGF , ERBB signaling pathways and in the regulation of gene expression, proliferation, cellular response to hypoxia, and negative regulation of the apoptotic process, the GO terms have central importance in ovarian cancer development. The aberrantly expressed miRNAs might be considered as potential biomarkers for the diagnosis of ovarian cancer after validation of these results in a larger cohort of ovarian cancer patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
ovarian cancer
circulating miRNA
blood plasma
NanoString
network analysis
bimarker
Megjelenés:International Journal Of Molecular Sciences. - 20 : 18 (2019), p. E4533. -
További szerzők:Márton Éva (1992-) (biológus) Soltész Beáta (1987-) (molekuláris biológus) Szilágyi Melinda (1984-) (biológus) Póka Róbert (1960-) (szülész-nőgyógyász, klinikai onkológus) Lukács János (1975-) (szülész-nőgyógyász, genetikus) Széles Lajos (1971-) (molekuláris biológus) Nagy Bálint (1956-) (molekuláris genetikus)
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM112946
035-os BibID:(cikkazonosító)10520 (WoS)001030973400001 (Scopus)85164844125
Első szerző:Pös, Ondrej (biológus)
Cím:Cross-Kingdom Interaction of miRNAs and Gut Microbiota with Non-Invasive Diagnostic and Therapeutic Implications in Colorectal Cancer / Pös Ondrej, Styk Jakub, Buglyó Gergely, Zeman Michal, Lukyova Lydia, Bernatova Kamila, Hrckova Turnova Evelina, Rendek Tomas, Csók Ádám, Repiska Vanda, Nagy Bálint, Szemes Tomas
Dátum:2023
ISSN:1422-0067
Megjegyzések:Colorectal cancer (CRC) has one of the highest incidences among all types of malignant diseases, affecting millions of people worldwide. It shows slow progression, making it preventable. However, this is not the case due to shortcomings in its diagnostic and management procedure and a lack of effective non-invasive biomarkers for screening. Here, we discuss CRC-associated microRNAs (miRNAs) and gut microbial species with potential as CRC diagnostic and therapy biomarkers. We provide rich evidence of cross-kingdom miRNA-mediated interactions between the host and gut microbiome. miRNAs have emerged with the ability to shape the composition and dynamics of gut microbiota. Intestinal microbes can uptake miRNAs, which in turn influence microbial growth and provide the ability to regulate the abundance of various microbial species. In the context of CRC, targeting miRNAs could aid in manipulating the balance of the microbiota. Our findings suggest the need for correlation analysis between the composition of the gut microbiome and the miRNA expression profile.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
colorectal cancer
biomarker
gut microbiota
microRNA
Megjelenés:International Journal Of Molecular Sciences. - 24 : 13 (2023), p. 1-21. -
További szerzők:Styk, Jakub Buglyó Gergely (1980-) (genetikus) Zeman, Michal Lukyova, Lydia Bernatova, Kamila Hrckova Turnova, Evelina Rendek, Tomas Csók Ádám (1994-) (biológus) Repiska Vanda Nagy Bálint (1956-) (molekuláris genetikus) Szemes, Tomas (1980-) (biológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM099574
035-os BibID:(cikkazonosító)8 (scopus)85121366077 (wos)000751087400001
Első szerző:Soltész Beáta (molekuláris biológus)
Cím:The Role of Exosomes in Cancer Progression / Soltész Beáta, Buglyó Gergely, Németh Nikolett, Szilágyi Melinda, Pös Ondrej, Szemes Tomas, Balogh István, Nagy Bálint
Dátum:2022
ISSN:1661-6596 1422-0067
Megjegyzések:Early detection, characterization and monitoring of cancer are possible by using extracellular vesicles (EVs) isolated from non-invasively obtained liquid biopsy samples. They play a role in intercellular communication contributing to cell growth, differentiation and survival, thereby affecting the formation of tumor microenvironments and causing metastases. EVs were discovered more than seventy years ago. They have been tested recently as tools of drug delivery to treat cancer. Here we give a brief review on extracellular vesicles, exosomes, microvesicles and apoptotic bodies. Exosomes play an important role by carrying extracellular nucleic acids (DNA, RNA) in cell-to-cell communication causing tumor and metastasis development. We discuss the role of extracellular vesicles in the pathogenesis of cancer and their practical application in the early diagnosis, follow up, and next-generation treatment of cancer patients.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:International Journal Of Molecular Sciences. - 23 : 1 (2022), p. 1-19. -
További szerzők:Buglyó Gergely (1980-) (genetikus) Németh Nikolett (1995-) (biológus) Szilágyi Melinda (1984-) (biológus) Pös, Ondrej (1990-) (biológus) Szemes, Tomas (1980-) (biológus) Balogh István (1972-) (molekuláris biológus, genetikus) Nagy Bálint (1956-) (molekuláris genetikus)
Pályázati támogatás:Operational Programme Integrated Infrastructure for the project ITMS2014+
Egyéb
313011V446 European Regional Development Fund
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.